Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sequenom, a provider of genetic analysis products, has signed an agreement to acquire the complete AttoSense portfolio of tests along with certain other assets from SensiGen, a privately held biotechnology company.
Subscribe to our email newsletter
The acquisition includes analytically validated, ultra-sensitive and ultra-specific tests for detection and monitoring of human papillomavirus (HPV), systemic lupus erythematosus, chronic kidney disease, inflammatory bowel disease, as well as other tests, all of which utilize Sequenom’s proprietary MassARRAY platform.
Under the terms of the agreement, Sequenom will acquire all of SensiGen’s currently developed assays, including the AttoSense HPV-G and HPV-Q tests for cervical cancer, AttoSense HPV-C for head and neck cancer, the AttoSense kidney test and the EpiSense lupus panel, along with certain other assets and intellectual property rights, in a stock and cash-based transaction. The total transaction purchase price of $8.7 million includes future earn-out milestone payments.
Harry Stylli, president and CEO of Sequenom, said: “The addition of SensiGen’s AttoSense tests to our portfolio represents a key step toward Sequenom’s goal to have a comprehensive offering of molecular diagnostics for women’s health and cancer.”